SCHEMBL6407334

SCHEMBL6407334

O=C1CCN(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.54
CYP3A4 P08684 5/20 0.54
USP2 O75604 5/20 0.52
CYP2C19 P33261 3/20 0.52
CYP1A2 P05177 2/20 0.52
TSHR P16473 6/20 0.49
CASP1 P29466 1/20 0.49
CASP5 P51878 1/20 0.49
HPGD P15428 1/20 0.48
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
LMNA P02545 1/20 0.47
TACR1 P25103 3/20 0.46
HIF1A Q16665 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.46
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4698249 0.84 KDM4E (0.70) ALDH1A1KDM4EGAALMNATACR1
SCHEMBL8108271 0.83 KDM4E (0.67) ALDH1A1KDM4ETACR1HIF1A
SCHEMBL4145765 0.83 KDM4E (0.67) ALDH1A1KDM4ETACR1HIF1A
SCHEMBL6028265 0.82 ALDH1A1 (0.67) CYP2D6CYP3A4USP2CYP2C19CYP1A2
SCHEMBL8974017 0.80 ALDH1A1 (0.60) CYP2D6CYP3A4USP2CYP2C19CYP1A2
SCHEMBL31010361 0.80 ALDH1A1 (0.70) CYP2D6CYP3A4USP2CYP2C19CYP1A2
SCHEMBL10819405 0.77 CHKA (0.57) CYP2D6CYP3A4USP2CYP2C19CYP1A2
SCHEMBL5544345 0.77 CYP2D6 (0.55) CYP2D6CYP3A4USP2CYP2C19CYP1A2
SCHEMBL19262510 0.77 CYP2D6 (0.72) CYP2D6CYP3A4USP2CYP2C19CYP1A2
SCHEMBL19625264 0.77 CYP2D6 (0.55) CYP2D6CYP3A4USP2CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use TAKEDA CHEMICAL INDUSTRIES, LTD. 2005-02-17 US disclosed
EP-1460062-A1 NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use BDKRB1, BDKRB2, TACR1 CYP2D6 1333/4885CYP3A4 848/4885USP2 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.